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Background Existing evidence indicates that the risk of obstetric and perinatal outcomes is higher in
women with coronavirus infection. outbreaks suggest that pregnant women and their fetuses are
particularly susceptible to poor outcomes. However, there is little known about pregnancy related
complications and co-morbidity in this group of women. Therefore, this, systematic review and meta-
analysis performed in order to  nd out whether COVID-19 may cause different manifestations and
outcomes in antepartum and postpartum period or not.
Methods We searched databases, including Medline (PubMed), Embase, Scopus, Web of sciences,
Cochrane library, Ovid and CINHAL to retrieve all articles reporting the prevalence of maternal and
neonatal complications, in addition clinical manifestations, in pregnant women with COVID 19 that
published with English language from January to April 2020. Results 11 studies with total 177 pregnant
women included in this systematic review.
Results show that the pooled prevalence of neonatal mortality, lower birth weight, stillbirth, premature
birth, and intrauterine fetal distress in women with COVID 19 were 4% (95% Cl: 1 - 9%), 21% (95% Cl: 11 –
31%), 2% (95% Cl: 1 - 6%), 28% (95% Cl: 12 - 44%), and 15% (95% Cl: 4 - 26%); respectively. Also the pooled
prevalence of fever, cough, diarrhea and dyspnea were 56% (95% Cl: 30 - 83%), 30% (95% Cl: 21 - 39%), 9%
(95% Cl: 2 - 16%), and 3% (95% Cl: 1 - 6%) in the pregnant women with COVID-19.
Conclusion According to this systematic review and meta-analysis, the pregnant women with COVID-19
with or without pneumonia, are at a higher risk of pre-eclampsia, preterm birth, miscarriage and cesarean
delivery. Furthermore, the risk of LBW and intrauterine fetal distress seems increased in neonates.
Introduction
The global pandemic due to coronavirus has become a major burden in the world infecting over a million
patients (1). There are six different CoV strains in humans of which, severe respiratory syndrome
coronavirus (SARS-CoV) and Middle East respiratory Syndrome (MERS-CoV) are the most known types
(2). Coronavirus is an enveloped and single-strained ribonucleic acid having 9–12 nm-long surface
spikes. One of the four major proteins on the envelope binds to angiotensin converting enzyme2 (ACE2)
receptor for entering the host cell (3, 4). It was  rst reported in Wuhan, China, in December 2019, causing
a spectrum of symptoms from asymptomatic to death which are mostly nonspeci c. Respiratory signs
and symptoms accompanied with some other manifestations such as fever, sore throat, cough, diarrhea,
nausea, vomiting are the common symptoms of COVID-19 (5, 6). In blood test assay, patients might have
lower blood cell counts (Lymphopenia, thrombocytopenia,( and increased C-reactive protein level,
erythrocyte sedimentation rate, lactate dehydrogenase, creatinine, and a prolonged prothrombin time (7,
8). It can be transmitted through human-to-human contacts mainly by respiratory droplets (9).
According to the knowledge currently available in the literature about the susceptibility of pregnant
women to SARS-CoV and MERS-CoV, it seems that there should be a great attention to the coronavirus
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infection in pregnancy (10). There are several physiological changes during pregnancy which can make
the mother more susceptible to severe infections (11). The converted function of cardiorespiratory and
immune system, physiologic dyspnea due to increased maternal oxygen demands, the alteration in
pulmonary demands can put pregnant women at the risk of severe infection and hypoxic compromise as
well as misdiagnosis and mismanagement of routine upper respiratory tract symptoms (12, 13). Since
there is a great amount of ACE2 receptor expressed in the placenta, the scientists are concerned about the
possibility of vertical transmission (14, 15).
In this article, we have evaluated several factors such as maternal and neonatal complications,
therapeutic managements, signs and symptoms in pregnant women in a systematic review and meta-
analysis in order to  nd out whether COVID-19 may have a different manifestation and outcome in
antepartum and postpartum period or not.
Methods
This systematic review and meta-analysis was performed according to the Meta-Analyses of
Observational Studies in Epidemiology (MOOSE) and Preferred reporting items for systematic reviews
and meta-analyses (PRISMA) guidelines for reviews of analytical observational studies (16, 17).
Search Strategy and Screening
All original published articles were searched in international databases, including Medline (PubMed),
Embase, Scopus, Web of science, Cochrane library, Ovid and CINHAL to retrieve all articles reporting the
prevalence of maternal and neonatal complications, therapeutic managements, signs and symptoms in
pregnant women with COVID 19. Researchers performed a search of these databases, with hand
searching through the reference lists and grey literature. We searched in these search engines without
language limitations from January to April 2020. The search protocol developed based on four main
roots of “Maternal Complications”, “Neonatal Complications”, “Signs” and “Therapeutic Management”.
All related components to these keywords were “Maternal Complications” (“Preeclampsia”, “Preterm
Labor”, “Gestational Diabetes”, “Infections”, “Hypertension”, “Fetal Distress”, “Cesarean”, “Vaginal
Delivery”, and “Stillbirth”), “Neonatal Complications” (“Lower Birth Weight”, “C Reactive Protein”, “Liver
Function Test”, “Intrauterine Fetal Distress”, “Premature Birth”, “Neonatal Mortality”, and Lymphopenia),
“Signs” (“Fever”, “Caught”, “Malaise”, “Dyspnea”, “Myalgia”, “Sore Throat”, and “Diarrhea”) and
“Therapeutic Management” added to searched queries based on scienti c Mesh terms, EMTREE.
Reference Manager bibliographic software was used to manage searched citations. Duplicate entries
were searched by considering the title of the published papers, authors, the year of publication, and
speci cations of the sources types. In questionable records, the texts were compared. We reviewed the
primary search results, and after reviewing each article by title and available abstract, some of the articles
were eliminated. The evaluation of the papers under consideration was based on the inclusion and
exclusion criteria by the two researchers, separately (YM, MS).
Eligibility Criteria
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We included all observational studies which assessed the prevalence of maternal and neonatal
complications, therapeutic managements, signs and symptoms in pregnant women with COVID 19. We
excluded duplicate citations non-peer-reviewed, articles that the abstract and full text was not available,
and other languages.
Data Extraction
After three steps of assessment for titles, abstracts and full texts, the full text of each selected article was
retrieved for detailed analysis. Data were extracted using a checklist recording authors, publication year,
type of study, total of sample, gestational age, cesarean, vaginal delivery, chronic illness, indicators of
cesarean, complications of pregnancy, Signs and symptoms (fever on admission, cough, malaise,
dyspnea, myalgia, sore Throat, diarrhea, nausea and vomiting,  fetal movement, fetal heart rate, vaginal
bleeding, premature rupture of membrane, antepartum, post-partum), laboratory tests, imaging, treatment
and other parameters (abnormal Laboratory test, imaging, Bio Physical Pro le, maternal mortality,
maternal ICU admission, neonatal mortality, intrauterine fetal death, vertical transmission, treatments),
and infant characteristics (birth weight,  low birth weight, premature birth, Apgar score, intrauterine fetal
distress, severe neonatal asphyxia, neonatal death, fetal death or stillbirth). All processes from systematic
search to  nal data extraction were followed independently by two research experts (YM, MS) (Kappa
statistic for agreement for quality assessment; 0.97). Probable discrepancies were resolved by the main
investigator.
Risk of Bias
Qualitative evaluation of studies based on the Newcastle-Ottawa Quality Assessment Scale (NOS) (18)
was performed by two of the authors (YM and MS). This scale is designed to evaluate the qualitative
evaluation of observational studies. NOS examines each study by six items in three groups; selection,
comparability, and exposure. Stars are given to each item and the maximum score is 9. In case of
differences in the score assigned to the published articles, the external discussion method will be used.
Finally, the articles were categorized as low, moderate and high risk. The Strengthening the Reporting of
Observational studies in Epidemiology (STROBE) checklist was also completed for all articles (19, 20).
Statistical analysis
The random effects model was applied to calculate the pooled prevalence with 95% con dence interval
(95%CI) with Metaprop order. Heterogeneity across studies was evaluated using I2 value and reported as
a percentage (%) to determine the extent of variation between-studies. A forest plot was used to
schematically present the meta-analysis results. The Egger’s test and funnel plot were used for evaluating
the publication bias. In addition, a subgroup analysis was done to identify different sources of
heterogeneity. Statistical analysis was performed using STATA 16.0 (Stata Corp, College Station, TX,




306 articles were initially retrieved on the basis of the search strategies in the online databases. Among
these articles, 97 duplicate publications were identi ed and removed. The remained ones were screened
according to the titles and abstracts. 11 articles were selected as the  nal papers to be analyzed (Figure
1). The characteristics of 11 selected studies were demonstrated in Table 1. A total number of 177
pregnant women with COVID-19 were evaluated all in 2020 through 8 retrospectives, 1 case control, and 2
case report studies. The factors assessed in these studies involve gestational age, cesarean, vaginal
delivery, chronic illness, indicators of cesarean, complications of pregnancy, signs and symptoms (fever
on admission, cough, malaise, dyspnea, myalgia, sore throat, diarrhea, nausea and vomiting,  fetal
movement, fetal heart rate, vaginal bleeding, premature rupture of membrane, antepartum, post-partum),
laboratory tests, imaging, treatment and other parameters (abnormal laboratory test, imaging, Bio
Physical Pro le, maternal mortality, maternal ICU admission, neonatal mortality, intrauterine fetal death,
vertical transmission, treatments), and infant characteristics (birth weight,  low birth weight, premature
birth, Apgar score, intrauterine fetal distress, severe neonatal asphyxia, neonatal death, fetal death or
stillbirth) (Table 1). Some studies had not reported the method of treatment. The studies which have
reported the therapies applied for the patients have used both antibiotics and antivirals such as
Oseltamiovir, Ganciclovir, Azithromycin and Ceftazidime. Two studies have used corticosteroids and two
studies have used Chinese traditional medications which both of them had not explained about any
bene ts for the patients.
Quantitative analysis
Pooled prevalence of signs and symptoms in pregnant women with COVID 19
The least reported prevalence of fever in pregnant women with COVID 19 was 17% (95% Cl: 2 - 33%) in
the study by Wang X. et al. and the highest fever as prevalence was recorded 86% (95% Cl: 60- 98%) in the
retrospective study by Yu. et al. In total, the pooled prevalence of fever has been estimated as 56% (95%
Cl: 30 - 83%; I2= 92.02%; P -Value < 0.01) (Figure 2 and Table 2). The Meta Regression was used to
explore relationship of independent variables (age and gestational age) with the pooled prevalence of
primary outcomes. The results of Meta regression showed that the prevalence of fever has not any
relationship with age (coe cient: 0.029, P: 0.293, 95% CI: -0.026, 0.032), and gestational age of pregnant
women with COVID 19 (coe cient: 0.023, P: 0.451, 95% CI: -0.021, 0.026).
The pooled prevalence of cough has been estimated as 30% (95% Cl: 21 - 39%; I2= 0.0%; P -Value = 0.37)
(Figure 3 and Table 2). The least reported prevalence of cough in pregnant women with COVID 19 was
14% (95% Cl: 12 - 40%) in the study by Yu. et al. and the highest prevalence was recorded 55% (95% Cl:
25- 84%) in the retrospective study by Liu. et al (Figure 3). The results of Meta regression showed that the
prevalence of cough has relationship with age (coe cient: 0.08, P: 0.001, 95% CI: 0.005, 0.010), and
gestational age of pregnant women with COVID 19 (coe cient: 0.007, P: 0.001, 95% CI: 0.006, 0.011).
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Also the pooled prevalence of dyspnea has been estimated as 3% (95% Cl: 1 - 6%; I2= 0.0%; P -Value =
0.76) (Figure 3 and Table 2). The least and highest reported prevalence of dyspnea in pregnant women
with COVID 19 was 2% (95% Cl: 2 - 5%) and 50% (95% Cl: 19 - 95%), respectively (Figure 4 and Table 2).
The results of Meta regression showed that the prevalence of dyspnea has relationship with age
(coe cient: -0.0178, P: 0.046, 95% CI: -0.035, -0.000), and gestational age of pregnant women with COVID
19 (coe cient: -0.099, P: 0.326, 95% CI: -0.298, 0.099).
 The pooled prevalence of myalgia, sore throat, and diarrhea in pregnant women with COVID 19 were 18%
(95% Cl: 1 - 35%, I2= 49.84%; P -Value = 0.14), 7% (95% Cl: 1 - 13%, I2= 0.0%; P -Value = 0.55), and 9% (95%
Cl: 2 - 16%, I2= 0.0%; P -Value = 0.97), respectively (Table 2). The results of Meta regression showed that
the prevalence of myalgia, sore throat, and diarrhea have not any relationship with age and gestational
age of pregnant women with COVID 19.
Pooled prevalence of infant characteristics in pregnant women with COVID 19
The least reported prevalence of premature birth in pregnant women with COVID 19 was 8% (95% Cl: 1 -
16%) in the study by Schwartz. et al. and the highest premature birth as prevalence was recorded 50%
(95% Cl: 19 - 81%) in the retrospective study by Guo. et al. In total, the pooled prevalence of premature
birth has been estimated as 28% (95% Cl: 13 - 43%; I2= 81.57%; P -Value = 0.00) (Figure 5 and Table 3).
The results of Meta regression showed that the prevalence of premature birth has not relationship with
age (coe cient: -0.014, P: 0.343, 95% CI: -0.044, 0.015), and gestational age of pregnant women with
COVID 19 (coe cient: -0.055, P: 0.239, 95% CI: -0.147, 0.036).
The pooled prevalence of intrauterine fetal distress has been estimated as 15% (95% Cl: 4 - 26%; I2=
62.09%; P -Value = 0.04) (Figure 6 and Table 2). The least reported prevalence of intrauterine fetal
distress in pregnant women with COVID 19 was 4% (95% Cl: 4 - 13%) in the study by Wang X. et al. and
the highest intrauterine fetal distress as prevalence was recorded 30% (95% Cl: 2- 58%) in the
retrospective study by Guo. et al (Figure 6 and Table 3). The results of Meta regression showed that the
prevalence of intrauterine fetal distress has relationship with age (coe cient: 0.018, P: 0.003, 95% CI:
0.006, 0.030), but has not relationship with gestational age of pregnant women with COVID 19
(coe cient: -0.018, P: 0.851, 95% CI: -0.206, 0.170).
The pooled prevalence of neonatal mortality and lower birth weight in women with COVID 19 were 4%
(95% Cl: 1 - 9%; I2= 0.0%; P -Value = 0.52) and 21% (95% Cl: 11 - 31%; I2= 0.0%; P -Value = 0.97),
respectively. Also the pooled prevalence of stillbirth was 2% (95% Cl: 1 - 6%; I2= 0.0%; P -Value = 0.40).
The Lymphopenia prevalence in in women with COVID 19 were 37% (95% Cl: 17 - 56%; I2= 85.17%; P -
Value = 0.00) (Table 3). The results of Meta regression showed that the prevalence of Lymphopenia has
not relationship with age (coe cient: 0.029, P: 0.085, 95% CI: -0.004, 0.638), and gestational age of
pregnant women with COVID 19 (coe cient: 0.053, P: 0.500, 95% CI: -0.102, 0.209).
Pooled prevalence of Laboratory tests in pregnant women with COVID 19
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The pooled prevalence of increase CRP and LFT in women with COVID 19 were 58% (95% Cl: 40 - 75%; I2=
14.13%; P -Value = 0.13) and 32% (95% Cl: 11 - 52%; I2= 0.0%; P -Value = 0.88), respectively (Table 3). The
results of Meta regression showed that the prevalence of increase CRP has not relationship with age
(coe cient: 0.013, P: 0.440, 95% CI: -0.020, 0.047), and gestational age of pregnant women with COVID
19 (coe cient: -0.052, P: 0.672, 95% CI: -0.293, 0.189).
Pooled prevalence of complications in pregnancy and Cesarean indications in pregnant women with
COVID 19
Results of this meta-analysis show that the pooled estimate of preeclampsia and fetal distress in women
with COVID 19 were 26% (95% Cl: 3 - 54%; I2= 89.13%; P -Value = 0.00) (Table 4).
Publication Bias Assessment
The results of Egger’s test show no signi cant bias occurred in the publication of the results (Egger's test
= 1.15, SE: 0.480, P = 0.216).
Discussion
A total number of 177 pregnant women with COVID-19 were evaluated all in 2020 through 8 retrospective
(21-28), 1 case control (29), and 2 case report studies (30, 31). The purpose of this systematic review and
meta-analysis was to investigate the prevalence and relationship of several factors associated with
COVID-19 in pregnancy and the effect of these factors on the maternal and neonatal outcome. Although
a meta-analysis has been already published (32), we tried to have an update on this subject because of
the fast rate of publications about the new data on COVID-19. We attempted to  nd out the severity of
COVID-19 in pregnancy for providing optimum and on time diagnosis to prevent side effects and poor
outcomes. In some cases, which the data was completely presented, we could carry out the meta-
analysis.
The results of this paper demonstrate that the common signs and symptoms in pregnant women are
fever, myalgia, increased CRP, increased LFT and Lymphopenia. As it was mentioned in results, the
prevalence of fever, myalgia, sore throat and diarrhea was not related to age and gestational age of
pregnant women, while cough and dyspnea had relationship with age and gestational age. About the
neonatal factors, the prevalence of premature birth and fetal distress were not correlated with age and
gestational age. Among laboratory tests also, Lymphopenia and increased CRP had not any correlation
with age and gestational age. All the pregnant women admitted to the hospital had radiological features
of COVID-19 pneumonia in CT scan or CXR. Their signs and symptoms were all similar to the non-
pregnant population. The prevalence of preterm birth was 28% which is a high rate in comparison with
healthy pregnancies. The rate of preeclampsia and cesarean section was more than the general
population. The most common adverse perinatal outcome was fetal distress (26%) accompanied with a
low rate of fetal death or stillbirth (2%) and neonatal death (4%). We investigated that there is not any
clinical evidence of vertical transmission in the newborns, but previous evaluations caused by similar
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viruses such as SARS and MERS were indicative of vertical transmission (33). Other studies on three
newborns showed elevated SARS-CoV IgM antibodies. But the reported nasopharyngeal samples were
negative (32, 34). Yang X et al reported an asymptomatic COVID-19 pregnant woman in the late period of
pregnancy. They did not  nd any intrauterine infection caused by vertical transmission (35). But another
study which has evaluated seven pregnant women with severe SARS-CoV-2, has demonstrated that the
vertical transmission of COVID-19 infection from mothers during the last days of pregnancy is possible.
The method of delivery in this study was C-section. So they concluded that the route of infection was
trans-placental. Therefore, there cannot be any advantage for C-section compared to vaginal delivery
(36). Rose et al also reported another case of severe COVID-19 during pregnancy. They believe there is a
concern for vertical transmission and suggest an exact care for pregnant women as a high risk group
(30). So we believe that the possibility of maternal-fetal transmission could not be ruled out completely.
In our systematic review, women suffering from COVID-19 had higher rates of preeclampsia and preterm
birth. The fetuses had higher rates of fetal distress and the babies had higher rates of LBW. These data
are retrieved from the women in the third trimester of pregnancy. The underlying diseases in pregnant
women were gestational hypertension, diabetes and hypothyroidism. One patient needed mechanical
ventilation which was not related to any underlying disease. One patient had multi organ dysfunction
syndrome (MODS) leading to one stillbirth. One baby had severe neonatal asphyxia. Apgar score was in
the normal range in all neonates (except one stillbirth and one asphyxia). Three women had voluntary
termination. Two studies had twins, so 4 out of 13 LBW babies were due to twin delivery. But they all had
normal infant characteristics without any evidence of COVID-19.
There is a study that has reported two cases of maternal ICU admissions. But these cases had underlying
risk factors (high BMI>35) and complicated medical history (37). This can be a con rmation that COVID-
19 alone cannot increase the risk maternal and neonatal morbidity. Some other studies have applied C-
section for the majority of cases and reported that fetal distress was the major cause of decision for C-
section (21, 38). Since fetal distress in our study has not any relationship with age and gestational age of
pregnancy, so COVID-19 cannot be a cause of pregnancy termination by C-section.
There is a lack of data about the COVID-19 infection in the  rst and second trimester (32). On the basis of
the results of this systematic review, there should be a multidisciplinary team of gynecologists,
obstetricians, infection disease specialists and neonatologist to decide about the method of delivery (C-
section or vaginal delivery). The indications should be evaluated more carefully.
Strengths
This is a comprehensive meta-analysis involving 11 valid publications and evaluating 177 pregnant
women on this topic. Most of studies had an appropriate study population. The possibility that some
patients were included in more than one report was low. The number of case reports in our assay was




The major limitations of this systematic review were the poor reports about the exact indications of C-
section. We believe that most of C-sections were not necessary. Furthermore, the reported data about the
pregnant women whose pregnancy was not terminated during the admission was limited. There was not
a clear data about the neonates admitted in NICU. This can cause overestimation or underestimation of
the risk of COVID-19 in pregnancy.
Conclusion
According to this systematic review and meta-analysis, the pregnant women with COVID-19 with or
without pneumonia, are at a higher risk of preeclampsia, preterm birth, stillbirth and unnecessary
cesarean delivery. Furthermore, the babies are at increased risk of LBW and intrauterine fetal distress.
Although there cannot be any vertical transmission between mother and the fetus, the evidences show
that it is still controversy. Hence, it is recommended to perform complete and exact evaluation of COVID-
19 for the pregnant women at the time of admission. Chest CT-scan and RT-PCR testing seems to be
necessary in these cases in order to prevent antenatal and postnatal complications and have a better
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Table 1: Patient characteristics, Maternal outcomes and complications, Signs and symptoms Laboratory tests, imaging, treatment and other
parameters and Infant characteristics
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Abbreviations:
LFT: liver function tests, PROM: premature rupture of membrane, MODS: multiple organ dysfunction syndrome, NR: not reported, FHR: fetal heart
rate, VB: vaginal bleeding, PROM: premature rupture of membrane, AP: antepartum, PP: post-partum, NR: not reported, NL: normal, AB: antibiotic,
AV: antivirus, CT scan: computed tomography scan, CXR: chest X ray, CRP: C-reactive protein, LFT: liver function tests, WBC: white blood cells,
ALK-P: alkaline phosphatase, LDH: lactate dehydrogenase, Alb: albumin, PLT: platelet, ESR: estimated sediment rate, AP: antepartum, PP: post-




Table 2: Meta-analysis of prevalence of Signs and Symptoms COVID 19 in pregnant women by Random Effect Model (REM)
Outcomes  No. of Studies (Sample Size)
 
Pooled Prevalence (%) 95% Confidence Interval Heterogeneity Assessment (%)
I2 Q test P value
Fever  7 (126) 56 % 30 - 83 92.02 % 75.22 0.00
Cough  6 (110) 30 % 21 - 39 7.86 % 5.43 0.37
Malaise  3 (58) 13 % 1 - 28 45.58 % 3.68 0.16
Dyspnea 10 (176) 3 % 1 - 6 0.0 % 5.85 0.76
Myalgia 3 (58) 18 % 1 - 35 49.84 % 3.99 0.14
Sore Throat 5 (70) 7 % 1 - 13 0.0 % 3.06 0.55
Diarrhea 4 (65) 9 % 2 - 16 0.0 % 0.26 0.97
Increase CRP  5 (51) 58 % 40 – 75 % 14.13 % 7.16 0.13
Increase LFT  2 (19) 32 % 11 – 52 % 0.0 % 0.02 0.88
Lymphopenia 7 (126) 37 % 17 – 56 % 85.17 % 40.46 0.00
 
Table 3: Meta-analysis of prevalence of Laboratory tests and infant characteristics in pregnant women with COVID 19 by Random Effect Model
(REM)









I2 Q test P value
Neonatal Mortality 2 (65) 4 % 1 – 9 % 0.0 % 0.42 0.52
LBW 3 (63) 21 % 11 – 31 % 0.0 % 0.05 0.97
Premature Birth  6 (151) 28 % 12 – 44 % 81.57 % 27.12 0.00
Intrauterine Fetal
Distress
5 (96) 14 % 4 – 25 % 60.06 % 10.01 0.04




Table 4: Meta-analysis of prevalence of complications in pregnancy and Cesarean indications in pregnant women with COVID 19 by Random Effect
Model (REM)
Outcomes  No. of Studies (Sample Size)
 
Pooled Prevalence (%) 95% Confidence Interval Heterogeneity Assessment (%)
I2 Q test P value
Preeclampsia  4 (68) 26 % 3 – 54 89.13 % 27.59 0.00
Fetal Distress 3 (57) 26 % 15 – 38 0.00 % 0.15 0.93
Cesarean  5 (94) 86 % 75 – 95 43.48 % 7.08 0.13
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Figure 2
The pooled prevalence of Fever in pregnant women with COVID 19
Figure 3
The pooled prevalence of caught in pregnant women with COVID 19
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Figure 4
The pooled prevalence of Dyspnea in pregnant women with COVID 19
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Figure 5
The pooled prevalence of premature birth in pregnant women with COVID 19
Figure 6
The pooled prevalence of Intrauterine fetal distress in pregnant women with COVID 19
